DNA异常甲基化在肺癌诊疗中的应用进展  

Advances in the application of aberrant DNA methylation in the diagnosis and treatment of lung cancer

作　　者：杨雨 陈彦丽 赵晓涛[1] Yang Yu;Chen Yanli;Zhao Xiaotao(Department of Laboratory Medicine,Peking University People's Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院检验科,北京100044

出　　处：《中华预防医学杂志》2023年第8期1292-1297,共6页Chinese Journal of Preventive Medicine

基　　金：北京市自然科学基金(7172225)。

摘　　要：随着肺癌发病率与死亡率的增加,肺癌的早期诊断愈发成为临床诊疗关注的重点。DNA异常甲基化发生在肺癌早期,并随着疾病的进展及治疗动态变化。迄今为止,越来越多的研究报道特异性基因异常甲基化在肺癌诊断、疗效监测及预后评估方面的应用,同时DNA甲基转移酶抑制剂应用于肺癌治疗的临床试验也正在进行。DNA异常甲基化检测助力肺癌诊疗值得期待。The early diagnosis of lung cancer has become the focus of clinical attention,with the incidence and mortality of lung cancer increasing.Aberrant DNA methylation occurs in the primary stage of lung cancer,then the methylation degree can be changed dynamically due to the progress and the treatment of lung cancer.To date,a growing number of studies have reported that special gene methylation exploits in the clinical diagnosis,curative effect monitoring,and prognosis evaluation of lung cancer.Meanwhile,clinical trials about DNA methyltransferase inhibitors for lung cancer therapy are also underway.It is worth looking forward that detecting aberrant DNA methylation helps diagnose and treat lung cancer.

关 键 词：肺肿瘤 表观基因组学 DNA甲基化 DNA甲基转移酶抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]